Enhancing cisplatin drug sensitivity through PARP3 inhibition

• Verfasst von: Varol, Ayşegül [VerfasserIn]
• Verfasst von: Klauck, Sabine [VerfasserIn]
• Verfasst von: Dantzer, Françoise [VerfasserIn]
• Verfasst von: Efferth, Thomas [VerfasserIn]
• Titel: Enhancing cisplatin drug sensitivity through PARP3 inhibition
• Titelzusatz: the influence on PDGF and G-coupled signal pathways in cancer
• Verf.angabe: Ayşegül Varol, Sabine M. Klauck, Françoise Dantzer, Thomas Efferth
• E-Jahr: 2024
• Jahr: 1 August 2024
• Umfang: 12 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar: 1. Juni 2024, Artikelversion: 8. Juni 2024 ; Gesehen am 03.01.2025
• Titel Quelle: Enthalten in: Chemico-biological interactions
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1969
• Jahr Quelle: 2024
• Band/Heft Quelle: 398(2024) vom: Aug., Artikel-ID 111094, Seite 1-12
• ISSN Quelle: 1872-7786
• DOI: doi:10.1016/j.cbi.2024.111094
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Chemotherapy
• Sach-SW: Drug resistance
• Sach-SW: Prognostic factors
• Sach-SW: Signal transduction
• Sach-SW: Survival analysis
• Sach-SW: Transcriptomics
• K10plus-PPN: 1913489825

Abstract

Drug resistance poses a significant challenge in cancer treatment despite the clinical efficacy of cisplatin. Identifying and targeting biomarkers open new ways to improve therapeutic outcomes. In this study, comprehensive bioinformatic analyses were employed, including a comparative analysis of multiple datasets, to evaluate overall survival and mutation hotspots in 27 base excision repair (BER) genes of more than 7,500 tumors across 23 cancer types. By using various parameters influencing patient survival, revealing that the overexpression of 15 distinct BER genes, particularly PARP3, NEIL3, and TDG, consistently correlated with poorer survival across multiple factors such as race, gender, and metastasis. Single nucleotide polymorphism (SNP) analyses within protein-coding regions highlighted the potential deleterious effects of mutations on protein structure and function. The investigation of mutation hotspots in BER proteins identified PARP3 due to its high mutation frequency. Moving from bioinformatics to wet lab experiments, cytotoxic experiments demonstrated that the absence of PARP3 by CRISPR/Cas9-mediated knockdown in MDA-MB-231 breast cancer cells increased drug activity towards cisplatin, carboplatin, and doxorubicin. Pathway analyses indicated the impact of PARP3 absence on the platelet-derived growth factor (PDGF) and G-coupled signal pathways on cisplatin exposure. PDGF, a critical regulator of various cellular functions, was downregulated in the absence of PARP3, suggesting a role in cancer progression. Moreover, the influence of PARP3 knockdown on G protein-coupled receptors (GPCRs) affects their function in the presence of cisplatin. In conclusion, the study demonstrated a synthetic lethal interaction between GPCRs, PDGF signaling pathways, and PARP3 gene silencing. PARP3 emerged as a promising target.